Emavusertib; 1801344-14-8; Emavusertib [INN]; AU-4948; Emavusertib [USAN]; MH5DMF9JKY; CA4948; (R)-N-(5-(3-Hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide; 4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-; CHEMBL4783351; N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide; 2-(2-methylpyridin-4-yl)-N-[2-morpholin-4-yl-5-[(3R)-3-oxidanylpyrrolidin-1-yl]-[1,3]oxazolo[4,5-b]pyridin-6-yl]-1,3-oxazole-4-carboxamide; 4-Oxazolecarboxamide, N-(5-((3R)-3-hydroxy-1-pyrrolidinyl)-2-(4-morpholinyl)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methyl-4-pyridinyl)-; N-(5-((3R)-3-Hydroxy-1-pyrrolidinyl)-2-(4-morpholinyl)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methyl-4-pyridinyl)-4-oxazolecarboxamide; N-[5-[(3R)-3-Hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-4-oxazolecarboxamide; UNII-MH5DMF9JKY; Emavusertib [USAN:INN]; Emavusertib(CA-4948); Emavusertib (CA-4948); SCHEMBL16896638; GTPL10152; DTXSID001103300; EX-A4736; AU4948; BDBM50547964; NSC824184; s9779; WHO 11558; NSC-824184; compound 24 [PMID: 33335659]; AC-36757; HY-135317; CS-0111301; A937061; Z3769318307; FJ0; N-(5-((3R)-3-Hydroxypyrrolidin-1-yl)-2-(morpholin-4- yl)(1,3)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methylpyridin-4- YL)-1,3-oxazole-4-carboxamide; N-{5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-(morpholin-4-yl)[1,3]oxazolo[4,5-b]pyridin-6-yl}-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide